LYRA THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
LYRA THERAPEUTICS INC. - More news...
LYRA THERAPEUTICS INC. - More news...
- Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
- Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
- Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Lyra Therapeutics to Participate in Upcoming Investor Conferences
- Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer
- Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
- Lyra Therapeutics to Participate in Upcoming Investor Conferences
- Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
- Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
- Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Lyra Therapeutics to Present at Jefferies Healthcare Conference
- Lyra Therapeutics Announces Closing of $50.0 Million Private Placement
- Lyra Therapeutics Announces $50.0 Million Private Placement
- Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
- Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis
- Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer
- Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
- Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
- Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
- Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
- Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy